A Randomized, Open-label, Active Controlled, Safety And Extrapolated Efficacy Study In Pediatric Subjects Requiring Anticoagulation For The Treatment Of A Venous Thromboembolic Event

Trial Profile

A Randomized, Open-label, Active Controlled, Safety And Extrapolated Efficacy Study In Pediatric Subjects Requiring Anticoagulation For The Treatment Of A Venous Thromboembolic Event

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs Apixaban (Primary) ; Heparin; Low molecular weight heparins; Vitamin K antagonists
  • Indications Venous thromboembolism
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Bristol-Myers Squibb; Pfizer
  • Most Recent Events

    • 12 Jun 2017 Planned End Date changed from 28 Oct 2020 to 29 Oct 2020.
    • 12 Jun 2017 Planned primary completion date changed from 28 Oct 2020 to 29 Oct 2020.
    • 05 Jan 2016 Planned End Date changed from 1 Dec 2020 to 1 Oct 2020 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top